Clinical Trials Logo

Chronic HBV Infection clinical trials

View clinical trials related to Chronic HBV Infection.

Filter by:

NCT ID: NCT03909191 Completed - Clinical trials for Chronic HBV Infection

Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage

Start date: February 1, 2016
Phase:
Study type: Observational

As an alternative biomarker of intrahepatic covalently closed circular DNA(cccDNA) transcriptional activity, hepatitis B virus(HBV)RNA may evolve during long-lasting virus-host interactionsduring chronic hepatitis B viral infection.The distribution pattern of serum HBV RNA levels in the natural course of chronic HBV infection remains unclear. Furthermore,serum HBV RNA was associated with response to NAs. So it may be another clinical surrogate marker for intrahepatic cccDNA level after long-term NAs treatment and be used to monitor NAs therapy. The aim of this study was to evaluate thelevels of HBV RNA during the natural courseof CHB and the role in distinguishingthe natural phases of HBV infection and to investigate whether serum HBV RNA level at the end of long-term NAs treatment had a similar or better predict effect on off-therapy relapse than serum HBsAg titer.

NCT ID: NCT03903796 Active, not recruiting - Clinical trials for Chronic HBV Infection

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

Start date: August 16, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the safety and efficacy of HS-10234 versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT03664518 Completed - Clinical trials for Chronic HBV Infection

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

Start date: December 4, 2018
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate the efficacy of 6-week Eltrombopag to treat immune thrombocytopenia with chronic hepatitis B virus infection. Secondary Objective: To evaluate the efficacy and safety of 6-week and 22-week Eltrombopag to treat immune thrombocytopenia with chronic hepatitis B virus infection.

NCT ID: NCT01943799 Completed - Clinical trials for Chronic HBV Infection

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

Start date: September 13, 2013
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of GS-4774 in adults with chronic hepatitis B (CHB) viral infection who have been virally suppressed with an oral antiviral (OAV) medication.